Education
About Us
Working with TipRanks
Follow Us
Lenz Therapeutics, Inc. (LENZ)
:LENZ
LENZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.42 - $38.93
Previous CloseN/A
Volume24.39K
Average Volume (3M)220.45K
Market Cap
$633.49M
Enterprise Value$585.95M
Total Cash (Recent Filing)$19.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.40
Next Earnings
May 07, 2025EPS Estimate
-0.55Last Dividend Ex-Date
Mar 22, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-4.76
Shares Outstanding27,542,873
10 Day Avg. Volume253,257
30 Day Avg. Volume220,454
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-20.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-243.44
Enterprise Value/Ebitda-10.01
Forecast
1Y Price Target
$45.29Price Target Upside96.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
LENZ Therapeutics News
PremiumCompany Announcements
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook---
Bulls Say, Bears Say
Bulls Say
Market ReadinessPre-commercial planning efforts, commercial infrastructure, and completed mid-cycle review with the FDA indicate readiness for a prospective commercial launch of LNZ100.
Product DifferentiationLNZ100 is the first and only aceclidine-based daily topical eye drop for near vision improvement in presbyopia that explicitly does not utilize pilocarpine, offering a unique approach.
Regulatory ApprovalThere is continued optimism heading towards the PDUFA for prospective FDA approval.
Bears Say
Cash Flow ManagementThe company ended the quarter with $209M in cash, which management believes should be enough to fund operations to post-launch positive operating cash flow.
Operational DelaysThe company is holding a Commercial Day to go into more detail on launch plans in advance of expected approval.
Sales TimingLNZ100 sales are expected to commence only in 4Q25, despite the mid-3Q25 PDUFA, due to additional time required for final packaging after approval.
---
Ownership Overview
37.88% Insiders
5.81% Mutual Funds
0.16% Other Institutional Investors
48.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LENZ FAQ
What was Lenz Therapeutics, Inc.’s price range in the past 12 months?
Lenz Therapeutics, Inc. lowest stock price was $14.42 and its highest was $38.93 in the past 12 months.
What is Lenz Therapeutics, Inc.’s market cap?
Lenz Therapeutics, Inc.’s market cap is $633.49M.
When is Lenz Therapeutics, Inc.’s upcoming earnings report date?
Lenz Therapeutics, Inc.’s upcoming earnings report date is May 07, 2025 which is in 32 days.
How were Lenz Therapeutics, Inc.’s earnings last quarter?
Lenz Therapeutics, Inc. released its earnings results on Mar 19, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$0.05.
Is Lenz Therapeutics, Inc. overvalued?
According to Wall Street analysts Lenz Therapeutics, Inc.’s price is currently Undervalued.
Does Lenz Therapeutics, Inc. pay dividends?
Lenz Therapeutics, Inc. pays a Notavailable dividend of $1.029 which represents an annual dividend yield of N/A. See more information on Lenz Therapeutics, Inc. dividends here
What is Lenz Therapeutics, Inc.’s EPS estimate?
Lenz Therapeutics, Inc.’s EPS estimate is -0.55.
How many shares outstanding does Lenz Therapeutics, Inc. have?
Lenz Therapeutics, Inc. has 27,542,873 shares outstanding.
What happened to Lenz Therapeutics, Inc.’s price movement after its last earnings report?
Lenz Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went up 3.056%.
Which hedge fund is a major shareholder of Lenz Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LENZ
---
LENZ Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.29 (96.91% Upside)
$45.29 (96.91% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 9.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 14.8%
Last 30 Days ▲ 14.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.38%
12-Months-Change
Fundamentals
Return on Equity
-25.68%
Trailing 12-Months
Asset Growth
14.25%
Trailing 12-Months
Company Description
Lenz Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
---
LENZ Stock 12 Month Forecast
Average Price Target
$45.29
▲(96.91% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering LENZ
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+17.48%
reiterated a buy rating 16 days ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +17.48% per trade.
---